Wave closes $50M equity sale to GSK affiliate; collaboration effective, triggering $120M upfront

Wave Life Sciences Ltd.

Closed sale of 10,683,761 ordinary shares to Glaxo Group Limited for $50M cash.
Collaboration and License Agreement with GSK effective January 27, 2023.
GSK must now pay $120M upfront cash plus first research support funding.
Investor Agreement with GGL entered into as previously disclosed on Dec 13, 2022.

item 1.01 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Wave Life Sciences Ltd. entered into Investor Agreement with Glaxo Group Limited (effective 2023-01-26).

Action: entry
Counterparty: Glaxo Group Limited
Effective: 2023-01-26

Exact text from the filing

On January 26, 2023, as a condition to and simultaneous with the closing of the equity issuance contemplated by the Share Purchase Agreement (the “Share Purchase Agreement”), dated December 13, 2022, by and between Wave Life Sciences Ltd. (including its subsidiaries, the “Company” or “Wave”) and Glaxo Group Limited (“GGL”), the Company entered into an Investor Agreement with GGL (the “Investor Agreement”).

View on SEC.gov

Browse all material agreements →

Wave Life Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-23-018358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.